RxDoctor Payments Data

Alexander Evens, DO

Infectious Disease · Turlock, CANPI 1114144649

Payments from drug & device makers

$153,256in general payments, 2019–2025

Across 224 payments — averaging $684.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$141K
  • Tetraphase Pharmaceuticals, Inc.$11K
  • Coloplast$260
  • Shionogi Inc$233
  • GSK$125
  • La Jolla Pharmaceutical Company$55
  • plus $104 from 4 others

What the payments were for

  • Consulting fees$13,9759%
  • Speaking & faculty fees$95,20162%
  • Travel & lodging$39,67426%
  • Food & beverage$4,1273%
  • Education$2790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,256 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$220,798
Medicare patients
366
Services billed
1,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi41$186,509
BiktarvyBictegrav/Emtricit/Tenofov Ala37$140,920
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$50,569
DescovyEmtricitabine/Tenofov Alafenam11$27,263
IsentressRaltegravir Potassium11$25,016
CeftriaxoneCeftriaxone Sodium25$2,169
Daptomycin14$2,105
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)12$1,201
Itraconazole15$1,118
Cephalexin46$823
Cefazolin Sodium12$475
Potassium Citrate ErPotassium Citrate14$388
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$189
Furosemide15$119
Fluconazole11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$26$186,50941 claims
GileadBiktarvy, Descovy$23$168,18348 claims
MerckIsentress$141,094$25,01611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 856 infectious disease providers in California.

Other infectious disease in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →